PubMed:19891556 / 759-959 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"6782","span":{"begin":46,"end":57},"obj":"ChemicalEntity"},{"id":"6783","span":{"begin":111,"end":118},"obj":"GeneOrGeneProduct"},{"id":"6784","span":{"begin":131,"end":142},"obj":"ChemicalEntity"}],"attributes":[{"id":"A10","pred":"db_id","subj":"6782","obj":"MESH:D000077144"},{"id":"A11","pred":"db_id","subj":"6783","obj":"NCBIGene:1557"},{"id":"A12","pred":"db_id","subj":"6784","obj":"MESH:D000077144"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-sentences","denotations":[{"id":"T6","span":{"begin":0,"end":200},"obj":"Sentence"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T9","span":{"begin":101,"end":107},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":111,"end":118},"obj":"GeneOrGeneProduct"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T3","span":{"begin":101,"end":107},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":111,"end":118},"obj":"GeneOrGeneProduct"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T3","span":{"begin":111,"end":118},"obj":"GeneOrGeneProduct"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T13","span":{"begin":131,"end":142},"obj":"ChemicalEntity"}],"attributes":[{"id":"A13","pred":"ID:","subj":"T13","obj":"D000077144"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A15","pred":"ID:","subj":"T13","obj":"ChemicalEntity"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T13","span":{"begin":131,"end":142},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":111,"end":118},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A15","pred":"ID:","subj":"T13","obj":"ChemicalEntity"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D000077144"}],"text":"Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response."}